Alzheimer’s treatment donanemab is not a ‘miracle drug’ – not providing it on the NHS is the right choice
There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...
Donanemab – what we know about the latest Alzheimer’s drug
Donanemab can slow the progression of Alzheimer’s disease. But what is the drug and how does it work? Here your questions on ...
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study
Eli Lilly and Company (NYSE: LLY) today announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a ...
New Alzheimer’s drug donanemab rejected for widespread use in NHS
A new Alzheimer’s drug has been rejected by the health spending watchdog for general use within NHS England, with the ...
News Medical on MSN7d
MHRA greenlights donanemab for early stage Alzheimer’s disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...
Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS
Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...
Alzheimer’s drug approved in the UK, but it won’t be available on the NHS – here’s why
The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.
Alzheimer's 'wonder drug' Donanemab blocked for use on NHS over cost concerns
A drug that can slow the progression of Alzheimer's disease has been blocked for use on the NHS due to cost concerns.
News Medical7d
MHRA greenlights donanemab for early stage Alzheimer’s disease
Donanemab was evaluated in a main study (Phase III Study TRAILBLAZER-ALZ 2) involving 1,736 patients with early Alzheimer’s disease who had mild cognitive impairment, mild dementia and evidence ...
Surrey Alzheimer's drug trial patient shares his experience of donanemab
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...